C N Sternberg

Summary

Affiliation: Catholic University
Country: Italy

Publications

  1. ncbi request reprint Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007
  2. ncbi request reprint The management of bladder cancer in the elderly
    Cora N Sternberg
    Vincenzo Pansadoro Foundation, Rome
    Tumori 88:S128-9. 2002
  3. pmc An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
    Eugenio Donato Di Paola
    Department of Medical Oncology, San Camillo and Forlanini Hospitals Rome, Italy Department of Science of Health, School of Medicine, University Magna Graecia Catanzaro, Italy
    Front Oncol 2:175. 2012
  4. pmc Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    BMC Urol 13:58. 2013
  5. doi request reprint Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 24:1017-25. 2013
  6. doi request reprint A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Eur J Cancer 49:1287-96. 2013
  7. doi request reprint ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Eur Urol 63:58-66. 2013
  8. ncbi request reprint Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
    Andrea Zivi
    Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Rome, Italy
    Expert Opin Drug Saf 11:851-9. 2012
  9. doi request reprint Expanding the boundaries of clinical practice: building on experience with targeted therapies
    C N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Ann Oncol 20:i1-6. 2009
  10. doi request reprint Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    J Clin Oncol 27:5431-8. 2009

Detail Information

Publications69

  1. ncbi request reprint Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007
    ....
  2. ncbi request reprint The management of bladder cancer in the elderly
    Cora N Sternberg
    Vincenzo Pansadoro Foundation, Rome
    Tumori 88:S128-9. 2002
  3. pmc An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors
    Eugenio Donato Di Paola
    Department of Medical Oncology, San Camillo and Forlanini Hospitals Rome, Italy Department of Science of Health, School of Medicine, University Magna Graecia Catanzaro, Italy
    Front Oncol 2:175. 2012
    ..Conclusions: In this phase Ib study, the combination of satraplatin and gemcitabine demonstrated to be safe and efficacious in particular in patients with prostate cancer...
  4. pmc Treatment patterns and characteristics of European patients with castration-resistant prostate cancer
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    BMC Urol 13:58. 2013
    ..The aim of this analysis was to evaluate the management of CRPC patients across five European countries (France, Germany, Italy, Spain and the UK)...
  5. doi request reprint Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 24:1017-25. 2013
    ..This is the first phase III study in advanced prostate cancer to evaluate fatigue outcomes using a validated fatigue-specific instrument...
  6. doi request reprint A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Eur J Cancer 49:1287-96. 2013
    ..Final overall survival (OS) and updated safety results are now reported...
  7. doi request reprint ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Eur Urol 63:58-66. 2013
    ..We present a summary of the Second International Consultation on Bladder Cancer recommendations on chemotherapy for the treatment of bladder cancer using an evidence-based strategy...
  8. ncbi request reprint Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
    Andrea Zivi
    Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Rome, Italy
    Expert Opin Drug Saf 11:851-9. 2012
    ..In particular, dysregulation of the vascular endothelial growth factor (VEGF) pathway and VEGF protein overexpression have proved important, as they result in increased tumor angiogenesis and RCC growth and development...
  9. doi request reprint Expanding the boundaries of clinical practice: building on experience with targeted therapies
    C N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Ann Oncol 20:i1-6. 2009
    ..Targeted agents have considerably improved the prognosis for patients with these cancers...
  10. doi request reprint Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    J Clin Oncol 27:5431-8. 2009
    ....
  11. ncbi request reprint Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, IT 00152 Rome, Italy
    Oncology 68:2-9. 2005
    ..Its role in the treatment of HPRC remains to be elucidated in an appropriate phase III setting...
  12. ncbi request reprint Chemotherapy for local treatment of bladder cancer
    Cora N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, 00152 Rome, Italy
    Semin Radiat Oncol 15:60-5. 2005
    ..The role of adjuvant chemotherapy remains undefined...
  13. ncbi request reprint Satraplatin in the treatment of hormone-refractory prostate cancer
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Nuovi Padiglioni, Circonvallazione Gianicolense 87, 00152 Rome, Italy
    BJU Int 96:990-4. 2005
  14. doi request reprint Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 20:1264-9. 2009
    ..This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer...
  15. ncbi request reprint What's new in the treatment of advanced prostate cancer?
    C N Sternberg
    Chief, Department of Medical Oncology, San Camillo Forlanini Hospital, Vincenzo Pansadoro Foundation, Via Aurelia 559, 00165 Rome, Italy
    Eur J Cancer 39:136-46. 2003
    ....
  16. ncbi request reprint Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
    C N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th Floor, Circonvallazione Gianicolense 87, Rome 00152, Italy
    Eur J Cancer 42:50-4. 2006
    ..9%). With longer follow-up initial results have been confirmed, and shows that HD-M-VAC produces a borderline statistically significant relative reduction in the risk of progression and death compared to M-VAC...
  17. ncbi request reprint Adjuvant chemotherapy for bladder cancer
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Nuovi Padiglioni IV Floor, Circonvallazione Gianicolense 87, 00152 Rome, Italy
    Expert Rev Anticancer Ther 5:987-92. 2005
    ..The results of appropriately sized randomized trials are needed before any definitive conclusions can be drawn...
  18. ncbi request reprint Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    BJU Int 97:435-8. 2006
  19. ncbi request reprint Novel targeted therapy for advanced renal carcinoma: trials in progress
    Fabio Calabrò
    San Camillo Forlanini Hospital, Padiglione Flajani, Rome, Italy
    Curr Opin Urol 20:382-7. 2010
    ..This review provides an updated survey of the recently reported and ongoing clinical trials that will help to further define the role of these novel drugs in the treatment of renal cell carcinoma...
  20. doi request reprint The future of prostate cancer
    Cora N Sternberg
    San Camillo Hospital, Rome, Italy
    BJU Int 101:934-6. 2008
  21. ncbi request reprint Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours
    Cora N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Pavilion Cesalpino II, Circonvallazione Gianicolense 87, Rome 00152, Italy
    Eur J Oncol Nurs 8:S4-15. 2004
    ..The increasing availability of capecitabine in the home-based setting requires careful consideration of the role of the oncology nurse, who is the key link between the patient and clinician for effective and efficient management...
  22. doi request reprint Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
    ..CONCLUSION Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC...
  23. ncbi request reprint Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organ
    C N Sternberg
    Vincenzo Pansadoro Foundation, Rome, Italy
    J Clin Oncol 19:2638-46. 2001
    ....
  24. ncbi request reprint Neo-adjuvant chemotherapy in invasive bladder cancer
    C N Sternberg
    Vincenzo Pansadoro Foundation, Via Aurelia 559, Rome, 00165 Italy
    World J Urol 19:94-8. 2001
    ..The true success of bladder-preserving treatment by chemotherapy with or without RT will require validation in prospective randomized trials...
  25. ncbi request reprint Second-line treatment of advanced transitional cell carcinoma of the urothelial tract
    C N Sternberg
    Vincenzo Pansadoro Foundation, Clinic Pio XI, Rome, Italy
    Curr Opin Urol 11:523-9. 2001
    ..The rationale for using epidermal growth factor receptor targeted therapies is also reviewed...
  26. ncbi request reprint Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy
    C N Sternberg
    Vincenzo Pansadoro Foundation, Rome, Italy
    Cancer 92:2993-8. 2001
    ..An every-2-week regimen of gemcitabine and paclitaxel was adapted for patients with advanced transitional cell carcinoma (TCC) who had received prior cisplatin-based chemotherapy...
  27. ncbi request reprint Current perspectives in muscle invasive bladder cancer
    C N Sternberg
    Vincenzo Pansadoro Foundation, Clinic Pio XI, Via Aurelia 559, 00165, Rome, Italy
    Eur J Cancer 38:460-7. 2002
    ....
  28. ncbi request reprint Highlights of contemporary issues in the medical management of prostate cancer
    Cora N Sternberg
    Department of Medical Oncology, Vincenzo Pansadoro Foundation, Via Aurelia 559, Rome, Italy
    Crit Rev Oncol Hematol 43:105-21. 2002
    ..Chemotherapy in hormone refractory prostate cancer (HRPC) is extensively covered as well as the emerging role of molecular-targeted therapies...
  29. ncbi request reprint Overview of international collaborative group prostate cancer trials
    Cora N Sternberg
    Department of Medical Oncology, Vincenzo Pansadoro Foundation, Via Aurelia 559, Rome, Italy
    Crit Rev Oncol Hematol 43:153-8. 2002
    ..It is essential to treat patients with prostate cancer in the framework of clinical trials since there are still many unanswered questions...
  30. ncbi request reprint Can patient selection for bladder preservation be based on response to chemotherapy?
    Cora N Sternberg
    Vincenzo Pansadoro Foundation, Rome, Italy
    Cancer 97:1644-52. 2003
    ....
  31. ncbi request reprint Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, 00152, Rome, Italy
    Crit Rev Oncol Hematol 46:S105-15. 2003
    ..The molecular biology of these diseases is being unravelled and as knowledge accumulates, our ability to target these cancers will continue to increase...
  32. ncbi request reprint What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?
    Cora N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy, and EORTC Data Center, Biostatistics Department, Brussels, Belgium
    BJU Int 98:487-9. 2006
  33. ncbi request reprint Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder
    C N Sternberg
    San Raffaele Scientific Institute, Rome, Italy
    Ann Oncol 10:1301-5. 1999
    ..The purpose of this study was the evaluation of neo-adjuvant M-VAC chemotherapy and bladder preservation in patients with locally advanced transitional cell carcinoma of the bladder...
  34. ncbi request reprint New drugs and new approaches for the treatment of metastatic urothelial cancer
    Fabio Calabrò
    Vincenzo Pansadoro Foundation, Clinic Pio XI, Via Aurelia 559, Rome, Italy 00165
    World J Urol 20:158-66. 2002
    ..Molecular targeted small molecule therapy and monoclonal antibodies have begun to dominate contemporary studies. Whether or not this approach to therapy will lead to better results must still be determined...
  35. ncbi request reprint New treatments for metastatic kidney cancer
    Andrea Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Can J Urol 12:66-70; discussion 105. 2005
    ..This review, analyzing basic translational research principles, will summarize the available data on the use of these new therapeutic approaches in RCC...
  36. ncbi request reprint Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?
    C N Sternberg
    Medical Oncology, Vincenzo Pansadoro Foundation, Clinic Pio XI, Rome, Italy
    Ann Oncol 13:273-9. 2002
  37. ncbi request reprint New treatment approaches in metastatic renal cell carcinoma
    Andrea Mancuso
    Department of Medical Oncology, San Camillo Hospital, Rome, Italy
    Curr Opin Urol 16:337-41. 2006
    ..This review, analyzing basic translational research principles, will summarize the available evidence with a glimpse of the future therapeutic approaches in renal cell carcinoma...
  38. ncbi request reprint Metastatic renal cell cancer treatments
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Drugs Today (Barc) 39:39-59. 2003
    ..Adequate positioning of known treatments is essential and many trials of new targeted therapies are underway...
  39. ncbi request reprint High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG)
    V Pansadoro
    Vincenzo Pansadoro Foundation and San Giovanni Hospital, Rome, Italy
    J Exp Clin Cancer Res 22:223-7. 2003
    ..We describe our long term experience of therapy of G3T1 bladder cancer...
  40. ncbi request reprint State-of-the-art management of metastatic disease at initial presentation or recurrence
    Fabio Calabrò
    Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th Floor, Circonvallazione Gianicolense 87, Rome 00152, Italy
    World J Urol 24:543-56. 2006
    ....
  41. ncbi request reprint The evolving role of chemotherapy in advanced urothelial cancer
    Fabio Calabrò
    Department of Medical Oncology, San Camillo Forlanini Hospitals, Rome, Italy
    Curr Opin Support Palliat Care 1:180-6. 2007
    ..This review focuses on chemotherapy in the management of patients with advanced urothelial cancer, with a look towards the future and the next generation of clinical trials...
  42. doi request reprint Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
    C N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Ann Oncol 19:vii91-5. 2008
  43. doi request reprint Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma
    Fabio Calabrò
    Department of Medical Oncology, San Camillo Forlanini Hospitals, Circonvallazione Gianicolense 87, Rome 00152 Italy
    Cancer 115:2652-9. 2009
    ..A multicenter trial was initiated in 5 Italian centers to evaluate this regimen as first-line chemotherapy...
  44. ncbi request reprint Current therapies and advances in the treatment of pancreatic cancer
    Andrea Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, Rome, Italy
    Crit Rev Oncol Hematol 58:231-41. 2006
    ..To date, second line therapy is increasingly proposed and may even provide survival benefits in the future. This article summarizes the current standards of therapy for patients with resectable, advanced and metastatic pancreatic cancer...
  45. ncbi request reprint Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation
    Cora N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Semin Oncol 34:122-8. 2007
    ..The urologic oncology community should actively support recruitment to ongoing adjuvant chemotherapy trials in order to answer this important question...
  46. ncbi request reprint Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments
    Andrea Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense, 87 Rome, Italy
    Crit Rev Oncol Hematol 61:176-85. 2007
    ..In addition, new targeted therapies under development in combination with taxanes are reviewed with an explanation of their molecular mechanisms of action...
  47. ncbi request reprint Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey
    A Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Anticancer Res 30:4289-95. 2010
    ....
  48. pmc Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study
    C N Sternberg
    Regina Elena Cancer Institute, Rome, Italy
    Br J Cancer 70:376-9. 1994
    ..Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma...
  49. ncbi request reprint What's new in the treatment of metastatic kidney cancer?
    Andrea Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    BJU Int 95:1171-80. 2005
  50. doi request reprint Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer
    Fabio Calabrò
    San Camillo Forlanini Hospital, Rome, Italy
    Eur Urol 55:348-58. 2009
    ..The use of neoadjuvant and adjuvant chemotherapy in the treatment of muscle-invasive bladder cancer is still controversial...
  51. doi request reprint Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
    C N Sternberg
    San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 25:429-34. 2014
    ..4 versus 13.6 months (hazard ratio, HR) 0.63 (95% confidence interval, CI, 0.53-0.75); P<0.001] compared with placebo in patients with metastatic castration-resistant prostate cancer who received prior docetaxel chemotherapy...
  52. ncbi request reprint Current indications for chemotherapy in prostate cancer patients
    Fabio Calabrò
    San Camillo Forlanini Hospitals, Rome, Italy
    Eur Urol 51:17-26. 2007
    ....
  53. ncbi request reprint Is there a role for presurgical therapy for renal cell carcinoma?
    Fabio Calabrò
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Padiglione Flajani, Circonvallazione Gianicolense 87, Rome, Italy
    Expert Rev Anticancer Ther 10:807-12. 2010
    ....
  54. ncbi request reprint Muscle invasive and metastatic bladder cancer
    C N Sternberg
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy
    Ann Oncol 17:x23-30. 2006
  55. ncbi request reprint Localized and locally advanced bladder cancer
    Fabio Calabrò
    Department of Medical Oncology, Vincenzo Pansadoro Foundation, Via Aurelia 559, Rome 00165, Italy
    Curr Treat Options Oncol 3:413-28. 2002
    ..A better understanding of the microbiology of bladder cancer will influence the search for new therapeutic modalities. Molecular-targeted small-molecule therapy and monoclonal antibodies have begun to dominate contemporary studies...
  56. ncbi request reprint The medical management of prostate cancer: a multidisciplinary team approach
    Cora N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    BJU Int 99:22-7. 2007
  57. ncbi request reprint High-risk metastatic urothelial cancer: chances for cure?
    Fabio Calabrò
    Vincenzo Pansadoro Foundation, Clinic Pio XI, Rome, Italy
    Curr Opin Urol 12:441-8. 2002
    ....
  58. ncbi request reprint Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience
    Vito Pansadoro
    Vincenzo Pansadoro Foundation, Rome, Italy
    Urology 59:227-31. 2002
    ..We report our 18-year experience in the treatment of patients with G3T1 bladder cancer...
  59. ncbi request reprint Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Andrea Mancuso
    Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, I 00152 Rome, Italy
    Crit Rev Oncol Hematol 55:67-81. 2005
    ....
  60. ncbi request reprint Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  61. ncbi request reprint Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, PA, US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Investig Drugs 17:253-61. 2008
    ..Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta and c-kit...
  62. ncbi request reprint Are nomograms better than currently available stage groupings for bladder cancer?
    Cora N Sternberg
    J Clin Oncol 24:3819-20. 2006
  63. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  64. ncbi request reprint Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy
    Fred Saad
    Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, 1560 Rue Sherbrooke East, Montreal, QC, Canada
    Nat Clin Pract Urol 4:S3-13. 2007
    ..The early diagnosis and treatment of bone loss and bone metastases with bisphosphonates are critical for the maintenance of skeletal wellness and prevention of bone complications in patients with prostate cancer...
  65. ncbi request reprint Management of advanced prostate cancer after first-line chemotherapy
    Dominik R Berthold
    Department of Medical Oncology, Princess Margaret Hospital, and University of Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 23:8247-52. 2005
    ....
  66. ncbi request reprint Signal-transduction inhibitors in renal cell carcinoma
    Nicholas J Vogelzang
    Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA
    BJU Int 99:1289-95. 2007
  67. doi request reprint Urologists and clinical trials
    Cora N Sternberg
    Nat Clin Pract Urol 5:229. 2008
  68. ncbi request reprint Prostate cancer chemotherapy. Interview by Christine McKillop
    Cora N Sternberg
    Eur Urol 51:1136-8. 2007
  69. ncbi request reprint Bladder cancer
    Filippo De Braud
    START Project, European School of Oncology, Viale Beatrice d Este 37, 20122 Milan, Italy
    Crit Rev Oncol Hematol 41:89-106. 2002
    ..Response rates to combination chemotherapy regimens of up to 70% in patients with advanced metastatic disease have led to an investigation of its use for locally invasive disease in combination with conventional modalities of treatment...